Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Metastatic Renal Cell Carcinoma Unsuitable for Nephrectomy
NCT01693822Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2012
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in metastatic renal cell carcinoma (mRCC), sponsored by The Institute of Cancer Research. Started Oct 2012; status: completed.
02
Drugs
axitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01693822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693822.